Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Lymphoma 1Hodgkin Disease 1Hematologic Neoplasms 1

Interventions

fludarabine phosphate 19fludarabine 18Cyclophosphamide 16Tacrolimus 12Whole-Body Irradiation 11Melphalan 11Mycophenolic Acid 10Bortezomib 9Busulfan 8trametinib 7Dexamethasone 7thymoglobulin 6Stem Cell Transplantation 6Lenalidomide 6Cyclosporine 6Sirolimus 5Nivolumab 5Methotrexate 5dabrafenib 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Granulocyte Colony-Stimulating Factor 4Antilymphocyte Serum 4Alemtuzumab 4daratumumab 3aldesleukin 3Thiotepa 3Specimen Handling 3Ipilimumab 3Interleukin-2 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × pevonedistat × Plasma cell × Clear all
NCT00722488 2013-11-18

Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma

Millennium Pharmaceuticals, Inc.

Phase 1 Completed
56 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡